I agree that this site is using cookies. You can find further informations here.
X
Lugowska, I.
57  results:
Search for persons X
?
1

61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadl..:

Reichardt, P. ; Schöffski, P. ; Lorusso, P....
ESMO Open.  9 (2024)  - p. 102451 , 2024
Link: https://doi.org/10.1016/..
 
?
2

22O Association of biomarkers with response to coformulated..:

Le Tourneau, C. ; Rojas, C.I. ; Leary, A....
ESMO Open.  9 (2024)  - p. 103522 , 2024
Link: https://doi.org/10.1016/..
 
?
3

21O Coformulated vibostolimab/pembrolizumab in advanced cer..:

Leary, A. ; Yonemori, K. ; Le Tourneau, C....
ESMO Open.  9 (2024)  - p. 103521 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guide..:

Lugowska, I. ; Becker, J.C. ; Ascierto, P.A....
ESMO Open.  9 (2024)  5 - p. 102977 , 2024
Link: https://doi.org/10.1016/..
 
?
5

44O Updated results from a phase I study evaluating the KRA..:

Rojas, C.I. ; Lugowska, I. ; Juergens, R....
ESMO Open.  9 (2024)  - p. 102273 , 2024
Link: https://doi.org/10.1016/..
 
?
6

25P Patient-reported outcomes (PROs) with coformulated vibo..:

Yonemori, K. ; Rojas, C.I. ; Leary, A....
ESMO Open.  9 (2024)  - p. 103525 , 2024
Link: https://doi.org/10.1016/..
 
?
7

123P A nomogram may predict survival of adolescent and youn..:

Rutkowski, P. ; Jagodzinska-Mucha, P. ; Kopec, S....
ESMO Open.  9 (2024)  - p. 102512 , 2024
Link: https://doi.org/10.1016/..
 
?
8

A phase II open-label trial of avelumab plus axitinib in pr..:

Galffy, G. ; Lugowska, I. ; Poddubskaya, E.V....
ESMO Open.  8 (2023)  3 - p. 101173 , 2023
Link: https://doi.org/10.1016/..
 
?
9

157P PCM4EU academy: An educational program for precision o..:

Verlingue, L. ; Antouly, M. ; Witczak, M...
ESMO Open.  8 (2023)  1 - p. 102006 , 2023
Link: https://doi.org/10.1016/..
 
?
10

A phase Ib/II dose expansion study of subcutaneous sasanlim..:

Cho, B.C. ; Penkov, K. ; Bondarenko, I....
ESMO Open.  8 (2023)  4 - p. 101589 , 2023
Link: https://doi.org/10.1016/..
 
?
11

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F)..:

Neven, P. ; Hamilton, E. ; Pistilli, B....
ESMO Open.  8 (2023)  1 - p. 101395 , 2023
Link: https://doi.org/10.1016/..
 
?
12

46O Preliminary results from a phase IA trial of selective ..:

Lugowska, I. ; Stanczak, A. ; Roszkowski, K....
ESMO Open.  8 (2023)  1 - p. 100904 , 2023
Link: https://doi.org/10.1016/..
 
?
13

72P MDM alterations in patients with advanced or metastatic..:

Lugowska, I. ; Kosela Paterczyk, H.M. ; Iwanski, M....
ESMO Open.  8 (2023)  1 - p. 100930 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patie..:

Dziadziuszko, R. ; Garralda Cabanas, E. ; Rojas, K....
European Journal of Cancer.  174 (2022)  - p. S23 , 2022
Link: https://doi.org/10.1016/..
 
?
15

115P Reflectance confocal microscopy: An in vivo method of ..:

Slowinska, M.A. ; Szumera-Cieckiewicz, A. ; Czarnecka, I....
Immuno-Oncology and Technology.  16 (2022)  - p. 100219 , 2022
Link: https://doi.org/10.1016/..
 
1-15